Home / Psoriasis / A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

  Purpose

The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165 tablet formulation.

Condition Intervention Phase
Systemic Lupus Erythematosus Arthritic Psoriasis Psoriasis Inflammatory Bowel Diseases Drug: BMS-986165 Capsule Drug: BMS-986165 Tablet Phase 1

Study Type: Interventional
Study Design:Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title:A Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study To Evaluate the Bioavailability of BMS-986165 Tablet Formulation Relative To BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal And Increased Gastric pH on the Bioavailability of BMS-986165 Tablet Formulation in Healthy Subjects

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:

  • Maximum observed plasma concentration (Cmax) derived from plasma concentration versus time [ Time Frame: 5 days ]
  • AUC from time zero extrapolated to infinity [AUC(INF)] derived from plasma concentration versus time [ Time Frame: 5 days ]
  • Area under the plasma concentration-time curve (AUC) from time zero to time of last quantifiable concentration [AUC(0-T)] derived from plasma concentration versus time [ Time Frame: 5 days ]
  • Time of maximum observed plasma concentration (Tmax) derived from plasma concentration versus time [ Time Frame: 5 days ]

Secondary Outcome Measures:

  • Adverse events measured by incidence [ Time Frame: 26 days ]
  • Serious adverse events measured by incidence [ Time Frame: Approximately 55 days ]

Estimated Enrollment:12
Actual Study Start Date:September 13, 2017
Estimated Study Completion Date:October 12, 2017
Estimated Primary Completion Date:October 11, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tablet-Capsule Crossover 1

Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
Drug: BMS-986165 Capsule

Oral capsule

Drug: BMS-986165 Tablet

Oral tablet
Experimental: Tablet-Capsule Crossover 2

Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
Drug: BMS-986165 Capsule

Oral capsule

Drug: BMS-986165 Tablet

Oral tablet
Experimental: Tablet-Capsule Crossover 3

Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
Drug: BMS-986165 Capsule

Oral capsule

Drug: BMS-986165 Tablet

Oral tablet
Experimental: Tablet-Capsule Crossover 4

Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
Drug: BMS-986165 Capsule

Oral capsule

Drug: BMS-986165 Tablet

Oral tablet
Experimental: Tablet-Capsule Crossover 5

Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
Drug: BMS-986165 Capsule

Oral capsule

Drug: BMS-986165 Tablet

Oral tablet
Experimental: Tablet-Capsule Crossover 6

Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
Drug: BMS-986165 Capsule

Oral capsule

Drug: BMS-986165 Tablet

Oral tablet

About

Check Also

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Study Description Go to  Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation. Condition …

Leave a Reply

Your email address will not be published. Required fields are marked *